Harbour Investments’s abrdn Life Sciences Investors HQL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18K Buy
1,104
+1,096
+13,700% +$18.3K ﹤0.01% 2955
2025
Q4
$138 Hold
8
﹤0.01% 3714
2025
Q3
$128 Hold
8
﹤0.01% 3622
2025
Q2
$102 Buy
8
+4
+100% +$49 ﹤0.01% 3512
2025
Q1
$51 Buy
+4
New +$54 ﹤0.01% 3499
2021
Q4
Sell
-652
Closed -$14K 3096
2021
Q3
$14K Buy
652
+13
+2% +$278 ﹤0.01% 2487
2021
Q2
$14K Hold
639
﹤0.01% 2541
2021
Q1
$13K Buy
+639
New +$13.2K ﹤0.01% 2453

Other funds holding HQL

Harbour Investments's HQL Position: Q1 2026 in Review

Harbour Investments increased its abrdn Life Sciences Investors (HQL) stake by 13,700% in Q1 2026, buying an estimated $18.3K and bringing the position to 1,104 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #2955.

Harbour Investments first reported a position in HQL in Q1 2021 and has held it in 8 quarters since. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

  • Harbour Investments held 1,104 shares of abrdn Life Sciences Investors worth $18K as of Q1 2026.
  • Harbour Investments bought 1,096 abrdn Life Sciences Investors shares in Q1 2026, an estimated $18.3K.
  • abrdn Life Sciences Investors made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #2955 holding.
  • Harbour Investments first reported a position in abrdn Life Sciences Investors in Q1 2021 and has held it in 8 quarters since.
  • 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.